01355-A: Expression of Vascular Endothelial markers in Canine Hemangiosarcoma and their use in Diagnostic Cytology Using Immunocytochemistry
Grant Status: Closed
Canine hemangiosarcoma is an aggressive malignant tumor of the blood vessels which occurs most commonly in the spleen, heart and skin. Patients diagnosed with hemangiosarcoma in a location other than the skin have a very poor prognosis and these patients generally die from their disease in a short amount of time despite aggressive treatments including surgery and chemotherapy. Currently this type of cancer is most accurately diagnosed by biopsying the tumor which involves removing a small piece of tissue or the entire tumor and examining it microscopically. Tissue is most often obtained during surgery which requires the patient to be anesthetized. Biopsy of these tumors, however, carries many risks including rupture of the tumor and uncontrollable bleeding which may lead to death. Fine needle aspiration of the tumor is a safer, more inexpensive and less invasive procedure whereby cancer cells are removed by use of a small needle placed through the skin and into the tumor. These cells are then smeared onto a glass slide and examined under a microscope. Fine needle aspiration can be performed on an awake or lightly sedated patient and carries less risk of bleeding or tumor rupture. However, the diagnosis of hemangiosarcoma is difficult using this method because the cells obtained can appear very similar to other types of cancerous cells. The goal of this study is to identify a special cellular marker that can be applied to the sample obtained by fine needle aspiration which will differentiate hemangiosarcoma from other similar cancers. The use of such a marker will allow canine hemangiosarcoma to be diagnosed more reliably through the use of fine needle aspiration and avoid costly and invasive surgery to obtain a diagnosis of this devastating disease. Thus far, we have been able to identify three human markers which cross-react with canine tissue. We have used the marker to successfully identify the types of cells that become cancerous in hemangiosarcoma. We have also looked at one of the markers in depth (named CD62E) to determine the sensitivity and specificity. The final results are still being determined, but will tell us how reliable this marker is in identifying the correct tissue and to make sure we have limited numbers of false positive or false negative tests.
None at this time.
Help Future Generations of Dogs
Participate in canine health research by providing samples or by enrolling in a clinical trial. Samples are needed from healthy dogs and dogs affected by specific diseases.